法国制药巨头赛诺菲宣布，将在德国法兰克福霍赫斯特的生物园区建设一座新的、现代化的胰岛素生产工厂。该项目投资金额约为13亿欧元，预计至2029年完工，届时将有数百名高素质专业人员在新的工厂工作。这一投资计划得到了德国联邦政府、黑森州政府和法兰克福市政府的支持，并需获得欧盟委员会的批准。
赛诺菲德国公司负责人海德伦·伊尔希克-哈杰夫表示，这一投资计划凸显了法兰克福生物园区在全球胰岛素生产中的关键作用，联邦和州政府对国家医药战略的大力支持对生物制药行业是一个重要信号。德国媒体报道指出，随着赛诺菲投资计划的推进，制药公司在德国的投资进一步增加。此前，美国制药公司礼来也计划在德国投资23亿欧元建设生产基地，显示了全球制药业巨头对德国市场的信心。
德国联邦外贸与投资署总经理罗伯特·赫尔曼表示，赛诺菲的投资计划体现了德国在制药领域的实力，政府将制药业视为未来经济支柱，推出的激励措施和改革正吸引全球制药业巨头对德国充满信心。这一系列投资不仅增强了德国在生物制药领域的竞争力，也为全球患者提供了更多高质量的医疗产品。
英语如下：
News Title: “Sanofi Investing Massively in New Insulin Factory in Germany”
Keywords: Sanofi, Germany, Insulin
News Content: French pharmaceutical giant Sanofi announced that it will build a new, state-of-the-art insulin production factory in the biotech park of Frankfurt-Höchst, Germany. The project, which is expected to be completed by 2029, is estimated to cost around 130 million euros and will employ hundreds of highly skilled professionals once operational. This investment plan has received support from the German federal government, the state government of Hesse, and the city of Frankfurt, and it requires approval from the European Commission.
Heidrun Illschik-Hägele, the head of Sanofi’s German operations, stated that this investment plan underscores the critical role of the Frankfurt biotech park in global insulin production and is a significant signal of the federal and state governments’ strong support for the national pharmaceutical strategy. German media reports pointed out that as Sanofi’s investment plan progresses, pharmaceutical companies’ investments in Germany are further increasing. Previously, American pharmaceutical company Eli Lilly also planned to invest 230 million euros in building a production base in Germany, demonstrating global pharmaceutical giants’ confidence in the German market.
Robert Hermann, the managing director of the German Federal Foreign Trade and Investment Agency, stated that Sanofi’s investment plan reflects Germany’s strength in the pharmaceutical sector, and the government’s view of the pharmaceutical industry as a pillar of the future economy, coupled with the incentives and reforms introduced, is attracting global pharmaceutical giants with confidence in Germany. These series of investments not only enhance Germany’s competitiveness in the biopharmaceutical sector but also provide more high-quality medical products for patients worldwide.
【来源】http://www.chinanews.com/gj/2024/08-01/10261983.shtml
Views: 1